Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2016

Jan M Bell; Thomas Gottlieb; Denise A Daley and Geoffrey W Coombs

# Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2016 survey was the fourth year to focus on blood stream infections, and included Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter species.

Seven thousand five hundred and sixty-five species, comprising Enterobacteriaceae (6,750, 89.2%), P. aeruginosa (723, 9.6%) and Acinetobacter species (92, 1.2%), were tested using commercial automated methods (Vitek 2, BioMérieux; Phoenix, BD) and results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2017). Of the key resistances, non-susceptibility to the third-generation cephalosporin, ceftriaxone, was found in 11.8%/11.8% of Escherichia coli (CLSI/EUCAST criteria) and 7.7%/7.7% of Klebsiella pneumoniae, and 11.1%/11.1% K. oxytoca. Non-susceptibility rates to ciprofloxacin were 12.8%/16.3% for E.coli, 3.8%/10.0% for K. pneumoniae, 0.8%/2.1% for K. oxytoca, 1.8%/5.6% for Enterobacter cloacae complex, and 5.5%/9.4% for Pseudomonas aeruginosa. Resistance rates to piperacillin-tazobactam were 3.1%/6.5%, 3.6%/7.1%, 14.1%/14.9%, 19.9%/22.3%, and 5.2%/11.8% for the same 4 species respectively. Twenty-eight isolates were shown to harbour a carbapenemase gene, 14 blaIMP, five blaOXA-23, two blaOXA-48-like, two blaNDM, one blaKPC, one blaGES, three blaIMP+OXA-23.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antibiotic resistance; bacteraemia; Gram-negative; Escherichia coli; Enterobacter; Klebsiella

# Introduction

Emerging resistance in common pathogenic members of the Enterobacteriaceae is a world-wide phenomenon, and presents therapeutic problems for practitioners in both the community and in hospital practice. The Australian Group on Antimicrobial Resistance (AGAR) commenced surveillance of the key Gram-negative pathogens, Escherichia coli and Klebsiella species in 1992. Surveys have been conducted biennially until 2008, when annual surveys commenced alternating between community and hospital onset infections (http://www.agargroup.org/surveys). In 2004, another genus of Gram-negative pathogens in which resistance can be of clinical importance, Enterobacter species, was added. E coli is the most common cause of community-onset urinary tract infection, while Klebsiella species are less common but are known to harbour important resistances. Enterobacter species are less common in the community, but of high importance due to intrinsic resistance to first-line antimicrobials in the community. Taken together, the three groups of species surveyed are considered to be valuable sentinels for multi-resistance and emerging resistance in enteric Gram-negative bacilli. In 2013, AGAR commenced the Enterobacteriaceae Sepsis Outcome Programme (EnSOP) which focused on the collection of resistance and some demographic data on all isolates prospectively from patients with bacteraemia. In 2015, Pseudomonas aeruginosa and Acinetobacter species were added, and the program referred to as GNSOP.

Resistances of particular interest include resistance to ß-lactams due to ß-lactamases, especially extended-spectrum ß-lactamases, which inactivate the third-generation cephalosporins that are normally considered reserve antimicrobials. Other resistances of interest are to agents important for treatment of these serious infections, such as gentamicin; and resistance to reserve agents such as ciprofloxacin, meropenem and colistin.

The objectives of the 2016 surveillance program were to:

1. monitor resistance in Enterobacteriaceae, P. aeruginosa and Acinetobacter species isolated from blood, cultures taken from patients presenting to the hospital or already in hospital,
2. examine the extent of co-resistance and multidrug resistance in the major species,
3. detect emerging resistance to newer last-line agents such as carbapenems, and
4. characterise the molecular basis of resistance to third-generation cephalosporins, quinolones, amikacin and carbapenems

# Methods

## Study Design

From 1st January to 31st December 2016, 32 laboratories across Australia collected either all or up to 200 isolates from different patient episodes of bacteraemia.

## Species identification

Isolates were identified using the routine method for each institution; Vitek®, Phoenix™ Automated Microbiology System, or where available mass spectrometry (MALDI-TOF).

## Susceptibility testing

Testing was performed by two commercial semi-automated methods, Vitek 2 (BioMérieux) or Phoenix (BD), which are calibrated to the ISO reference standard method of broth microdilution. Commercially available Vitek AST-N246 and AST-N247, or Phoenix NMIC-203 cards were utilized by all participants throughout the survey period. The CLSI M1001 and EUCAST v7.02 breakpoints from January 2017 have been employed in the analysis. For analysis of cefazolin, breakpoints of ≤4 for susceptible, ≥8 for resistant were applied due to the restricted minimum inhibitory concentration (MIC) range available on the commercial cards, recognising that the January 2017 breakpoint is actually susceptible ≤2 mg/L.

## Molecular confirmation of resistances

E.coli, Klebsiella spp., Proteus spp. and Salmonella spp. with ceftazidime or ceftriaxone MIC > 1 mg/L, or cefoxitin MIC > 8 mg/L; any other Enterobacteriaceae with cefepime MIC > 1 mg/L; all isolates with ciprofloxacin MIC > 0.25 mg/L; all isolates with meropenem MIC > 0.25 mg/L; all isolates with amikacin MIC > 32 mg/L, and all isolates with colistin MIC > 2 mg/L were referred to a central laboratory (University of Adelaide) for molecular confirmation of resistance.

All referred isolates were screened using real-time polymerase chain reaction (PCR) platform (LC-480) and published primers for the presence of blaTEM and blaSHV, CTX-M-type genes (groups 1, 2, 9, 8/25), plasmid-borne AmpC (blaCIT, blaDHA, blaEBC, blaACC, blaFOX, blaMOX), and carbapenemases genes (blaIMP, blaNDM, blaKPC, blaOXA-48-like, blaVIM, blaGES, blaSME, blaIMI).3-5

PCRs were also used to detect blaIMP types, known plasmid-mediated quinolone resistance mechanisms (qnr, efflux [qepA, oqxAB] and aac (6’)-Ib-cr), aminoglycoside ribosomal methytransferases (armA, rmtB, rmtC, rmtF), and mobile colistin resistance genes (mcr-1, mcr-2, cr-3).6-11 All referred E.coli were examined for membership of the O25b-ST131 clone.12 All isolates with demonstrated carbapenemase activity and any amikacin resistant isolates were also screened for OXA-23-like, -24, and -58 carbapenemases.13

All isolates with carbapenemase activity were subjected to whole genome sequencing using the Illumina MiSeq platform. Data were analysed using the Nullarbor bioinformatic pipeline.14 The pipeline was used to identify the multi-locus sequence type and the resistome.

# Results

The species isolated, and the numbers of each, are listed in Table 1. Enterobacteriaceae accounted for 89.2%, followed by P. aeruginosa (9.6%) and Acinetobacter species (1.2%). Of the Enterobacteriaceae, three genera - Escherichia (60.9%), Klebsiella (18.2%) and Enterobacter (8.2%) - contributed 87.2% of all isolates. Major resistances and non-susceptibilities for the top six ranked species are listed in Table 2. Non-susceptibility, (which includes both intermediately resistant and resistant strains), has been included for some agents because these figures provide information about important emerging acquired resistances. Multiple acquired resistances by species are shown in Table 3. Multi-resistance was detected in 21.2% of E.coli isolates, 9.9% of K. pneumoniae, and 17.1% of E. cloacae complex. A more detailed breakdown of resistances and non-susceptibilites by state and territory is provided in the online report from the group (http://www.agargroup.org/surveys).

Table 1. Species, blood cultures, 2016

| Species | Total |  |
| --- | --- | --- |
| Escherichia coli | 4,106 | 54.3% |
| Klebsiella pneumoniae | 955 | 12.6% |
| Pseudomonas aeruginosa | 723 | 9.6% |
| Enterobacter cloacae complex | 396 | 5.2% |
| Klebsiella oxytoca | 243 | 3.2% |
| Proteus mirabilis | 226 | 3.0% |
| Serratia marcescens | 175 | 2.3% |
| Enterobacter aerogenes | 127 | 1.7% |
| Salmonella species (non-typhoidal) | 116 | 1.5% |
| Citrobacter freundii | 77 | 1.0% |
| Morganella morganii | 69 | 0.9% |
| Citrobacter koseri | 51 | 0.7% |
| Acinetobacter baumannii complex | 48 | 0.6% |
| Salmonella species (typhoidal) | 32 | 0.4% |
| Klebsiella variicola | 19 | 0.3% |
| Raoultella ornithinolytica | 16 | 0.2% |
| Acinetobacter species | 16 | 0.2% |
| Enterobacter species | 14 | 0.2% |
| Providencia rettgeri | 13 | 0.2% |
| Other species (total n = 45) | 143 | 1.9% |
| **Total** | **7,565** |  |

Table 2. Non-susceptibility and resistance rates for the top six ranked species tested, 2016

|  |  | *Escherichia coli* (%) | | *Klebsiella pneumoniae* (%) | | *Pseudomonas aeruginosa* (%) | | *Enterobacter cloacae complex* (%) | | *Klebsiella oxytoca* (%) | | *Proteus mirabilis* (%) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antimicrobial | Category\* | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST |
| Ampicillin | I | 1.6 | – | † | † | na | na | † | † | † | † | 1.3 | - |
|  | R | 53.6 | 55.2 | † | † | na | na | † | † | † | † | 16.9 | 18.2 |
| Amoxycillin-clavulanate (2:1) ‡ | I | 12.6 | na | 4.6 | – | na | na | † | † | 5.0 | – | 6.4 | – |
|  | R | 8.3 | – | 4.9 | – | na | na | † | † | 9.9 | – | 2.7 | – |
| Piperacillin-tazobactam | R | 3.1 | 6.5 | 3.6 | 7.1 | 5.2 | 11.8 | 19.9 | 22.3 | 14.1 | 14.9 | 0.0 | 0.9 |
| Cefazolin | R | 24.2 | 24.2 | 11.2 | 11.2 | na | na | † | † | 66.7 | 66.7 | 17.4 | 17.4 |
| Cefoxitin | R | 3.7 | / | 4.4 | / | na | na | † | † | 0.4 | / | 0.4 | / |
| Ceftriaxone | NS | 11.8 | 11.8 | 7.7 | 7.7 | na | na | 27.0 | 27.0 | 11.1 | 11.1 | 0.4 | 0.4 |
| Ceftazidime | NS | 6.7 | 10.8 | 5.4 | 8.0 | 7.9 | 7.9 | 24.2 | 26.5 | 1.6 | 2.1 | 0.0 | 0.4 |
| Cefepime | NS | 5.5 | 9.1 | 3.3 | 6.1 | 2.9 | 6.2 | 6.1 | 12.9 | 1.2 | 1.2 | 0.4 | 0.4 |
| Meropenem | NS | 0.1 | 0.1 | 0.5 | 0.4 | 8.0 | 8.0 | 2.5 | 2.3 | 0.4 | 0.4 | 0.0 | 0.0 |
| Ciprofloxacin | NS | 12.8 | 16.3 | 3.8 | 10.0 | 5.5 | 9.4 | 1.8 | 5.6 | 0.8 | 2.1 | 1.8 | 3.6 |
| Gentamicin | R | 7.4 | 7.6 | 4.3 | 4.3 | 1.7 | 4.2 | 5.6 | 5.6 | 1.2 | 1.2 | 0.4 | 2.2 |
| Trimethoprim | R | 32.1 | 32.3 | 15.8 | 16.6 | na | na | 15.2 | 15.4 | 2.9 | 2.9 | 20.9 | 20.9 |
| Nitrofurantoin | R | 0.8 | 0.8 | 23.2 | / | na | na | 13.5 | / | 2.9 | / | † | † |

\* R = resistant, I = intermediate, NS = non-susceptible (intermediate + resistant), using criteria as published by the CLSI [2017] and EUCAST [2017].  
† Considered largely intrinsically resistant due to natural β-lactamases; – no intermediate category; / no breakpoints defined; na = not applicable (testing not recommended)  
‡ For EUCAST interpretation, the clavulanate is fixed at 2 mg/L, rather than a 2:1 ratio used in CLSI guidelines. As all susceptibility test cards used have a 2:1 ratio of clavulanate no EUCAST category has been applied.

Table 3. Multiple acquired resistances by species, 2016

|  |  | Number of acquired resistances (EUCAST breakpoints) | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Non-multi-resistant | | | | Cumulative% | Multi-resistant | | | | | | | | | | Cumulative% |
| Species | Total | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| Escherichia coli | 3,944 | 1,552 | 540 | 648 | 367 |  | 239 | 157 | 117 | 148 | 76 | 58 | 30 | 11 | 1 | 0 |  |
|  | % | 39.4 | 13.7 | 16.4 | 9.3 | 78.8% | 6.1 | 4.0 | 3.0 | 3.8 | 1.9 | 1.5 | 0.8 | 0.3 | 0.0 | 0.0 | 21.2% |
| *Klebsiella pneumoniae\** | 919 | 676 | 99 | 35 | 18 |  | 17 | 12 | 15 | 12 | 12 | 21 | 1 | 1 |  |  |  |
|  |  | 73.6 | 10.8 | 3.8 | 2.0 | 90.1% | 1.8 | 1.3 | 1.6 | 1.3 | 1.3 | 2.3 | 0.1 | 0.1 |  |  | 9.9% |
| *Enterobacter cloacae complex†* | 339 | 216 | 29 | 7 | 29 |  | 32 | 9 | 4 | 6 | 6 | 1 |  |  |  |  |  |
|  |  | 63.7 | 8.6 | 2.1 | 8.6 | 82.9% | 9.4 | 2.7 | 1.2 | 1.8 | 1.8 | 0.3 |  |  |  |  | 17.1% |
| *Proteus mirabilis* | 212 | 117 | 50 | 21 | 13 |  | 9 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |  |  |
|  |  | 55.2 | 23.6 | 9.9 | 6.1 | 94.8% | 4.2 | 0.5 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |  | 5.2% |
| *Serratia marcescens†* | 138 | 124 | 4 | 4 | 0 |  | 1 | 1 | 3 | 0 | 1 | 0 |  |  |  |  |  |
|  |  | 89.9 | 2.9 | 2.9 | 0.0 | 95.7% | 0.7 | 0.7 | 2.2 | 0.0 | 0.7 | 0.0 |  |  |  |  | 4.3% |
| *Klebsiella oxytoca\** | 234 | 61 | 130 | 2 | 14 |  | 20 | 2 | 2 | 1 | 2 | 0 | 0 | 0 |  |  |  |
|  |  | 26.1 | 55.6 | 0.9 | 6.0 | 88.5% | 8.5 | 0.9 | 0.9 | 0.4 | 0.9 | 0.0 | 0.0 | 0.0 |  |  | 11.5% |
| *Enterobacter. aerogenes†* | 124 | 78 | 6 | 4 | 27 |  | 7 | 0 | 2 | 0 | 0 | 0 |  |  |  |  |  |
|  |  | 62.9 | 4.8 | 3.2 | 21.8 | 92.7% | 5.6 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 |  |  |  |  | 7.3% |
| *Salmonella species (non-typhoidal)* | 109 | 101 | 4 | 1 | 3 |  | 0 | 0 | 0 | 0 | 0 | 0 |  |  |  |  |  |
|  | 92.7 | 3.7 | 0.9 | 2.8 | 100% | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |  |  |  |  | 0.0% |

\* Antibiotics included: amoxycillin-clavulanate, piperacillin-tazobactam, cefazolin, cefoxitin, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, nitrofurantoin, trimethoprim, meropenem; Antibiotics excluded: ampicillin (intrinsic resistance), tobramycin, norfloxacin, nalidixic acid, sulfamethoxazole-trimethoprim (high correlation with antibiotics in the included list)  
† Antibiotics included: piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, trimethoprim, meropenem  
Antibiotics excluded: ampicillin, amoxycillin-clavulanate, cefazolin, and cefoxitin, (all four due to intrinsic resistance); also excluded were ticarcillin-clavulanate, tobramycin, norfloxacin, nalidixic acid, sulfamethoxazole-trimethoprim (high correlation with antibiotics in the included list).

## *Escherichia coli*

Moderately high levels of resistance to ampicillin (and therefore amoxycillin) were maintained (53.6%/55.2%, CLSI/EUCAST criteria), with lower rates for amoxycillin-clavulanate (12.6%/- intermediate, 8.3%/- resistant). Non-susceptibility to third-generation cephalosporins was low ceftriaxone 11.8%/11.8%, ceftazidime 6.7%/10.8%). Moderate levels of resistance were detected to cefazolin (24.2%/24.2%) and trimethoprim (32.1%/32.3%). Ciprofloxacin non-susceptibility was found in 12.8%/16.3% of E.coli isolates. Resistance to gentamicin (7.4%/7.6%), piperacillin-tazobactam (3.1%/6.5%), cefepime (5.5%/9.1%) were low. Thirteen isolates (0.3%) had elevated meropenem MICs (≥ 0.5 mg/L). For the strains with ESBL phenotype, ciprofloxacin and gentamicin resistance was found in 58.2%/60.9% and 27.8%/28.0% respectively.

Most of the E.coli strains with extended-spectrum β-lactamase (ESBL) genes harboured genes of the CTX-M type (368/423 = 87%). Fifty-five percent of E.coli with CTX-M group 1 types were found to belong to sequence type 131 (O25b-ST131). ST131 accounted for 62% of E.coli ESBL phenotypes that were ciprofloxacin resistant (MIC >1 mg/L), and only 3% of ciprofloxacin susceptible ESBL phenotypes.

## *Klebsiella pneumoniae*

K. pneumoniae showed slightly higher levels of resistance to piperacillin-tazobactam and ceftazidime compared with E.coli, but lower rates of resistance to amoxycillin-clavulanate, cefazolin, ceftriaxone ciprofloxacin, gentamicin, and trimethoprim. Ten K. pneumoniae isolates had elevated meropenem MICs (see below). ESBLs were present in 66 of 82 (80%) presumptively ESBL-positive isolates of K. pneumoniae, 48 (73%) of which confirmed to be of the CTX-M type.

## Enterobacter species

Acquired resistance was common to piperacillin-tazobactam (19.9%/22.3% and 25.0%/29.0%), ceftriaxone (27.0%/27.0% and 33.1%/33.1%), ceftazidime (24.2%/26.5% and 29.1%/31.5%) and trimethoprim (15.2%/15.4% and 3.9%/3.9%) for E. cloacae complex and E. aerogenes, respectively. Cefepime resistance was less than 13%; ciprofloxacin and gentamicin resistance were both less than 10%. Twenty-three E. cloacae complex strains had elevated meropenem MICs.

## Carbapenemase resistance

Overall, 28 isolates (25 patients) in 15 institutions from six states/territories were found to harbour a carbapenemase gene. blaIMP-4 was detected in E. cloacae complex (7, from 6 patients), and in E.coli (one), K. pneumoniae (two), E. aerogenes (one), Morganella morganii (one), and Serratia marcescens (one); blaIMP-14 was detected in Pseudomonas aeruginosa (one); blaIMP-4+OXA-23 was detected in Acinetobacter baumannii (three, from two patients); blaOXA-23 was detected in A. baumannii (5, from 4 patients); blaNDM-4 was detected in one P. aeruginosa; blaNDM-1 was detected in one K. pneumoniae; blaOXA-181 was detected in one K. pneumoniae; blaOXA-48 was detected in one K. pneumoniae; blaKPC-2 was detected in one K. pneumoniae; blaGES-5 was detected in one P. aeruginosa.

# Discussion

The Australian Group on Antimicrobial Resistance has been tracking resistance in sentinel enteric Gram-negative bacteria since 1992. From 2008, surveillance was segregated into hospital versus community onset infections. The last year of hospital onset only surveillance was 2011.15 In 2013, the first survey of antimicrobial resistance among Enterobacteriaceae isolates from bacteraemic patients throughout Australia was conducted using an approach similar to that conducted by the European EARS-Net program. 2016 was the fourth survey of antimicrobial resistance among Enterobacteriaceae, and the second for P. aeruginosa and Acinetobacter spp. from bacteraemic patients through Australia.

CTX-M-producing E.coli and Klebsiella species and gentamicin- and ciprofloxacin-resistant E.coli continued to be a problem in patients with bacteraemia. Of concern is the high proportion of E.coli that belong to the O25b-ST131 clone. Carbapenem resistance attributable to acquired carbapenemases are still uncommon in patients with bacteraemia in Australia, although six different types (IMP, KPC, NDM, OXA-48-like, VIM, and GES) were detected from 15 of the participating institutions. Compared with many other countries in our region, resistance rates in Australian Gram-negative bacteria are still relatively low16, but similar to those observed in 2016 in many Western European countries http://ecdc.europa.eu/sites/portal/files/‌documents/AMR-surveillance-Europe-2016.pdf.

Multi-resistance is being increasingly observed, especially in E.coli and E. cloacae complex, both of which have multi-resistance rates (as defined by AGAR) above 17%. This is likely to drive more broad-spectrum antibiotic use, and increase the resistance selection pressure for important reserve classes, especially the carbapenemases.

# Agar participants

## ****Australian Capital Territory****

Peter Collignon and Susan Bradbury, Canberra Hospital

## ****New South Wales****

Thomas Gottlieb and Graham Robertson, Concord Hospital

Rodney Givney and Ian Winney, John Hunter Hospital

James Branley and Linda Douglass, Nepean Hospital

Peter Huntington, Royal North Shore Hospital

Sebastian van Hal and Bradley Watson, Royal Prince Alfred Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

## ****Northern Territory****

James McLeod, Alice Springs Hospital

Rob Baird and Jann Hennessy, Royal Darwin Hospital

## ****Queensland****

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory

Petra Derrington and Cheryl Curtis, Pathology Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland Princess Alexandra Hospital

Jenny Robson and Georgia Peachey, Sullivan Nicolaides Pathology

## ****South Australia****

Kelly Papanaoum and Xiao Chen, SA Pathology, Flinders Medical Centre

Morgyn Warner and Kija Smith, SA Pathology, Royal Adelaide Hospital and Women’s and Children’s Hospital

## ****Tasmania****

Pankaja Kalukottege and Kathy Wilson, Launceston General Hospital

Louise Cooley and David Jones, Royal Hobart Hospital

## Victoria

Denis Spelman and Rose Bernhard, Alfred Hospital

Paul Johnson and Frances Hurren, Austin Health

Tony Korman and Despina Kotsanas, Monash Health, Monash Medical Centre

Andrew Daley and Gena Gonis, Royal Women’s and Children’s Hospital

Mary Jo Waters and Lisa Brenton, St Vincent’s Hospital

## ****Western Australia****

Shalinie Perera and Ian Meyer, Joondalup Hospital

David McGechie and Denise Daley, PathWest Laboratory Medicine WA, Fiona Stanley Hospital

Ronan Murray and Jacinta Bowman, PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre

Michael Leung, PathWest Laboratory Medicine WA, remote WA

Owen Robinson and Geoffrey Coombs, PathWest Laboratory Medicine WA, Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler, St John of God Pathology

# Author Details

1Ms Jan M Bell, 2A /Prof Thomas Gottlieb, 3Ms Denise A Daley, 4,5 Prof Geoffrey W Coombs

1. University of Adelaide, Adelaide, South Australia, Australia
2. Concord Hospital, Concord, New South Wales
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
4. Antimicrobial Resistance and Infectious Diseases Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia
5. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding Author

A/Prof Thomas Gottlieb

Telephone: (02) 9767 7533

Email: thomas.gottlieb@health.nsw.gov.au

# References

1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Seventh Informational Supplement M100–S27. Villanova, PA, USA 2017.
2. European Committee on Antimicrobial Susceptibility Testing (2017). Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January 2017. Available at http://www.eucast.org/clinical\_breakpoints/. Accessed January 1, 2017.
3. Ellington MJ, Findlay J, Hopkins KL, Meunier D, Alvarez-Buylla A, Horner C, et al. Multicentre evaluation of a real-time PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria. International Journal of Antimicrobial Agents. 2016;47(2):151-4.
4. Roschanski N, Fischer J, Guerra B, Roesler U. Development of a Multiplex Real-Time PCR for the Rapid Detection of the Predominant Beta-Lactamase Genes CTX-M, SHV, TEM and CIT-Type AmpCs in Enterobacteriaceae. PLOS ONE. 2014;9(7):e100956.
5. Swayne R, Ellington MJ, Curran MD, Woodford N, Aliyu SH. Utility of a novel multiplex TaqMan PCR assay for metallo-β-lactamase genes plus other TaqMan assays in detecting genes encoding serine carbapenemases and clinically significant extended-spectrum β-lactamases. International Journal of Antimicrobial Agents. 2013;42(4):352-6.
6. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham DW. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. J Med Microbiol. 2013;62(Pt 12):1823-7.
7. Corrêa LL, Montezzi LF, Bonelli RR, Moreira BM, Picão RC. Revised and updated multiplex PCR targeting acquired 16S rRNA methyltransferases. International Journal of Antimicrobial Agents. 2014;43(5):479-81.
8. Doi Y, Arakawa Y. 16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. Clinical Infectious Diseases. 2007;45(1):88-94.
9. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8.
10. Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol. 2007;45(2):544-7.
11. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, et al. Novel Plasmid-Mediated Colistin Resistance Gene mcr-3 in Escherichia coli. MBio. 2017;8(3).
12. Dhanji H, Doumith M, Clermont O, Denamur E, Hope R, Livermore DM, et al. Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum beta-lactamases. Int J Antimicrob Agents. 2010;36(4):355-8.
13. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. International Journal of Antimicrobial Agents. 2006;27(4):351-3.
14. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor Github [Available from: https://github.com/tseemann/nullarbor .
15. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J, for the Australian Group for Antimicrobial Resistance. Gram-negative Survey 2011 Antimicrobial Susceptibility Report. 2011 Adelaide. Available from: http://www.agargroup.org/files/AGAR20GNB0820Report20FINAL.pdf
16. Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57(7):2981–2988.



© Commonwealth of Australia 2018 - ISSN: 2209-6051 (Online)

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permit­ted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to copyright@health.gov.au

Communicable Diseases Intelligence aims to disseminate information on the epidemiology and control of communicable diseases in Australia. Communicable Diseases Intelligence invites contri­butions dealing with any aspect of communicable disease epidemiology, surveillance or prevention and control in Australia. Submissions can be in the form of original articles, short reports, surveil­lance summaries, reviews or correspondence. Instructions for authors can be found in Commun Dis Intell 2016;40(1):E189–E193.

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia

http://www.health.gov.au/cdna

This journal is indexed by Index Medicus and Medline

**Disclaimer:** Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Editor:** Cindy Toms  
**Deputy Editor:** Phil Wright  
**Editorial and Production Staff:** Leroy Trapani, Kasra Yousefi  
**Editorial Advisory Board:** Peter McIntyre (Chair), David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk  
**Website:** http://www.health.gov.au/cdi

Communicable Diseases Intelligence is produced by Health Protection Policy Branch, Office of Health Protection, Australian Government, Department of Health, GPO Box 9848, (MDP 6) CANBERRA ACT 2601;

**Email:** cdi.editor@health.gov.au